Regulated information - Inside information argenx announces launch of proposed global offering

Regulated information - Inside information

argenx announces launch of proposed global offering

the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the

lives of people suffering from severe autoimmune diseases, announced today that it has commenced a global offering of $750 million (approximately

668.6 million) of ordinary shares, which may be represented by American Depository Shares ("ADSs"). The global offering

will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the

European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom. Each

of the ADSs represents the right to receive one ordinary share, nominal value of 0.10 per share. The U.S. offering and the European

private placement are expected to close simultaneously.

In addition, argenx intends to grant the underwriters

of the offering a 30-day option to purchase additional ordinary shares (which may be represented by ADSs) in an aggregate amount of up

to 15% of the total number of ordinary shares (including represented by ADSs) proposed to be sold in the offering, on the same terms and

Gifford Overseas Limited and entities affiliated with it have indicated an interest in purchasing on behalf of their clients an aggregate

of up to $200 million of ordinary shares in the offering at the offering price per share and on the same terms as the other purchasers

in the offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could

determine to sell more, fewer or no ordinary shares to these potential purchasers, and these potential purchasers could determine to purchase

more, fewer or no shares in the offering.

argenx's ADSs are currently listed on the

Nasdaq Global Select Market under the symbol "ARGX" and argenx's ordinary shares are currently listed on Euronext Brussels

under the symbol "ARGX".

J.P. Morgan, Morgan Stanley, Goldman Sachs &

Co. LLC, BofA Securities and TD Cowen are acting as joint bookrunning managers for the offering. Van Lanschot Kempen is acting as manager

The securities are being offered in the United

States pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange

Commission ("SEC"). A preliminary prospectus supplement relating to the securities being offered in the United States will

be filed with the SEC and will be available on the SEC's website at www.sec.gov.

When available, copies of the final prospectus

supplement and the accompanying prospectus relating to the U.S. offering may be obtained for free from J.P. Morgan Securities LLC, c/o

Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com, or by telephone

at (866) 803-9204; from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus

Department, by email at prospectus@morganstanley.com; from Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attn:

Prospectus Department, by email at prospectus-ny@ny.email.gs.com, or by telephone at 866-471-2526; from BofA Securities, NC1-022-02-25,

201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, by email at dg.prospectus_requests@bofa.com;

or from Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at Prospectus_ECM@cowen.com or by telephone at (833)

A request for the admission to listing and trading

of the ordinary shares (including the ordinary shares underlying the ADSs) on the regulated market of Euronext Brussels will be made following

pricing of the offering.

This press release is for information purposes

only and does not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to

any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted

or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. Reference is also made to the restrictions

set out in "Important information" below. This press release is not for publication or distribution, directly or indirectly,

in or into any state or jurisdiction into which doing so would be unlawful or where a prior registration or approval is required for such

argenx is a global immunology company committed

to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology

Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU,

the UK and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental

medicines within its therapeutic franchises.

For further information, please contact:

Forward-looking Statements

The contents of this announcement include statements

that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the

use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects,"

"intends," "may," "will," or "should," and include statements argenx makes concerning

the completion, timing and size of the proposed global offering and its expectations with respect to granting the underwriters a 30-day

option to purchase additional ordinary shares (which may be represented by ADSs). By their nature, forward-looking statements involve

risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's

actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors,

including argenx's expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical

trial and product development activities, regulatory approval requirements and commercialization of its products; argenx's reliance

on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability

to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and

argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product

candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's SEC filings and

reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and

reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking

statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation

to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required

Important information

This announcement is not an advertisement and

not a prospectus within the meaning of the Prospectus Regulation and has not been approved by the Dutch Authority for the Financial Markets

(Stichting Autoriteit Financi le Markten) or the Belgian Financial Services and Markets Authority (Autoriteit Financi le Diensten

en Markten) or any other European Supervisory Authority.

No public offering will be made and no one

has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States,

where any such action is required, including in the European Economic Area. In the European Economic Area, the offering to which this

press release relates will only be available to, and will be engaged in only with, qualified investors within the meaning of the Prospectus

No action has been or will be taken to offer

the ordinary shares to a retail investor established in the European Economic Area as part of the global offering. For the purposes of

In addition, in the United Kingdom, the transaction

to which this press release relates will only be available to, and will be engaged in only with persons who are "qualified investors"

(as defined in the Prospectus Regulation as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal)

Act 2018 (the UK Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of

the Financial Services and Markets Act (Financial Promotion) Order 2005, as amended (the Order), and/or (ii) who are high net worth

companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the

Order (all such persons together being referred to as "relevant persons"). The securities referred to herein are only available

to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant

persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

In connection with the offering, J.P. Morgan

Securities LLC (the "Stabilization Manager"), or any of its agents, on behalf of the underwriters may (but will be under no

obligation to), to the extent permitted by applicable law, over-allot ordinary shares or ADSs or effect other transactions with a view

to supporting the market price of the ordinary shares or ADSs at a higher level than that which might otherwise prevail in the open market.

The Stabilization Manager is not required to enter into such transactions and such transactions may be effected on any securities market,

over-the-counter market, stock exchange (including Euronext Brussels) or otherwise and may be undertaken at any time starting on the first

trading date and ending no later than 30 calendar days thereafter.

However, there will be no obligation on the

Stabilization Manager or any of its agents to effect stabilizing transactions and there is no assurance that stabilizing transactions

will be undertaken. Such stabilization, if commenced, may be discontinued at any time without prior notice. Save as required by law or